Skip to main navigation Skip to search Skip to main content

Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency

  • EK Halvas
  • , GM Aldrovandi
  • , Peter Balfe
  • , IA Beck
  • , VF Boltz
  • , JM Coffin
  • , LM Frenkel
  • , JD Hazelwood
  • , VA Johnson
  • , M Kearney
  • , A Kovacs
  • , DR Kuritzkes
  • , KJ Metzner
  • , DV Nissley
  • , M Nowicki
  • , S Palmer
  • , R Ziermann
  • , RY Zhao
  • , CL Jennings
  • , J Bremer
  • D Brambilla, JW Mellors

Research output: Contribution to journalArticle

102 Citations (Scopus)

Abstract

We determined the abilities of 10 technologies to detect and quantify a common drug-resistant mutant of human immunodeficiency virus type 1 (lysine to asparagine at codon 103 of the reverse transcriptase) using a blinded test panel containing mutant-wild-type mixtures ranging from 0.01% to 100% mutant. Two technologies, allele-specific reverse transcriptase PCR and a Ty1HRT yeast system, could quantify the mutant down to 0.1 to 0.4%. These technologies should help define the impact of low-frequency drug-resistant mutants on response to antiretroviral therapy.
Original languageEnglish
Pages (from-to)2612-4
Number of pages3
JournalJournal of Clinical Microbiology
Volume44
Issue number7
DOIs
Publication statusPublished - 1 Jul 2006

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Fingerprint

Dive into the research topics of 'Blinded, Multicenter Comparison of Methods To Detect a Drug-Resistant Mutant of Human Immunodeficiency Virus Type 1 at Low Frequency'. Together they form a unique fingerprint.

Cite this